Medidata Medidata

Press Release

Medidata Announces Launch of Medidata Detect, its Centralized Statistical Monitoring Solution for Clinical Trials

NEW YORK, NY -- August 13, 2020 -- Medidata, a Dassault Systèmes company, announced the launch of Medidata Detect, a centralized statistical monitoring solution that improves data quality and promotes patient safety in clinical trials for new medicines, vaccines and medical devices. Medidata Detect, part of Medidata’s industry-leading, regulatory-compliant and unified Medidata Rave Clinical Cloud platform, helps customers manage data quality, monitor site performance and promote patient safety by uncovering and finding errors, trends and anomalies in data through statistical algorithms and tests.

“Medidata Detect is a new and vital machine learning tool designed to improve data integrity and reduce trial risk,” said Glen de Vries, co-founder and co-CEO, Medidata. “Detect is another example of our continuous innovation that helps advance clinical trials with increased data accuracy and speed. It’s another way we’re working to get important new vaccines and therapeutics to patients in safer, faster ways.”

A report in the Journal of the American Medical Society (JAMA)* found almost a quarter of new drug submissions required one or more resubmissions before they were approved, with a median delay to approval of 435 days following the first unsuccessful submission. Medidata Detect uses one central system for aggregation and review of any number of data sources, flagging data errors, trends, and anomalies in real time. This translates into better quality data and decisions throughout the trial, and shortens each cycle review time by weeks.

Medidata Detect identifies known and unknown risks, and triggers corrective actions, which proactively minimize study delays and submission failures in trials. A foundational step in adopting a RBQM (risk-based quality management) approach to clinical development, Medidata Detect is able to define and manage study risks, expose unanticipated data anomalies and cut down on programmers’ time and effort through proprietary machine learning algorithms that require no customer programming.

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

* Sacks LV, Shamsuddin HH, Yasinskaya YI, Bouri K, Lanthier ML, Sherman RE, “Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012.” JAMA.2014;311(4):378–384.

About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,500 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.

Medidata and Medidata Rave are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systèmes.

About Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual experience twins of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Contact
Caroline Drucker
Senior Director, Head of Corporate Communications
+1-347-675-3222
cdrucker@medidata.com

Paul Oestreicher
Head of External Communications, Senior Writer
+1-917-536-3523
poestreicher@medidata.com